This company has been marked as potentially delisted and may not be actively trading.

Hologic (HOLX) Stock Forecast & Price Target

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HOLX Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	8 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$79.13	$79.13	$79.09	$78.00
Forecasted Upside	4.10% Upside	4.10% Upside	4.05% Upside	17.22% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Healthcare Companies	Broader Market
Consensus Rating Score	2.00	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	4.10% Upside	919.70% Upside	15.07% Upside
News Sentiment Rating	Neutral News See Recent HOLX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
1/28/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Hold (C)
1/12/2026	Argus 3 of 5 stars	David Toung 4 of 5 stars	Downgrade	Buy ➝ Hold
1/5/2026	Evercore 3 of 5 stars	Vijay Kumar 3 of 5 stars	Downgrade	Outperform ➝ In-Line	$79.00 ➝ $78.00	+4.61%
11/21/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold	$79.00	+6.58%
11/11/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tejas Savant Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$69.00 ➝ $76.00	+1.88%
11/4/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
10/23/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$70.00 ➝ $78.00	+5.51%
10/22/2025	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mason Carrico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$78.00 ➝ $76.00	+2.75%
10/22/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Cooper Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
10/22/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$78.00	+5.43%
Get the Latest News and Ratings for HOLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.
10/21/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Puneet Souda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$70.00 ➝ $78.00	+5.35%
10/21/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral
8/6/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Conor McNamara Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Outperform	$72.00 ➝ $87.00	+28.28%
7/31/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Garcia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$65.00 ➝ $70.00	+4.19%
7/9/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00 ➝ $80.00	+23.27%
2/6/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
12/13/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Doug Schenkel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
12/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Hold	$85.00	+12.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:39 PM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 4, 2026. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. is currently trading at $76.01, a price that sits just below the consensus price target of $78.42, suggesting that the stock may still have room to appreciate as analysts maintain a Hold rating. This valuation gap indicates that the market may not yet fully price in the company's recent operational improvements and strategic positioning.
The company recently secured a significant patent victory against Siemens Healthineers, with a court determining that Siemens infringed on Hologic's mammography patent. This legal win not only protects Hologic's intellectual property but also strengthens its competitive position in the breast imaging market, potentially leading to increased market share and revenue from its 3D digital mammography systems.
Hologic, Inc. has expanded the CE-IVDR mark for its Aptima HPV Test to include self-collected samples in cervical cancer screening. This regulatory approval broadens the test's applicability and accessibility, allowing for more flexible screening options that can improve patient compliance and expand the addressable market for Hologic's diagnostics segment.
New evidence presented at the Society of Breast Imaging Symposium backs Hologic's AI-powered mammography technology for detecting challenging cancers. This validation of its image analytics software and reading workstations enhances the clinical utility of its breast health solutions, potentially driving higher adoption rates among radiologists and healthcare providers.
Hologic, Inc. reported a year-over-year revenue growth of 2.5% in its most recent earnings report, demonstrating consistent top-line expansion. This growth, combined with the company's diversified portfolio across diagnostics, breast health, gynecological surgical, and skeletal health segments, provides a stable revenue base that can withstand sector-specific fluctuations.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

Hologic, Inc. is facing a significant corporate transition as Blackstone and TPG have completed their acquisition of the company for up to $79 per share, taking it private. This move ends public trading and removes the stock from the S&P 500, which may limit liquidity and accessibility for retail investors who prefer publicly traded equities.
The FDA has updated its recall of Hologic's BioZorb product, citing 252 injuries. This regulatory action poses a reputational risk and may result in financial liabilities, including potential compensation costs and legal fees, which could impact the company's profitability and brand trust in the medical device market.
Hologic, Inc. is experiencing a shortage of needles used for breast cancer detection due to a recall, with the company aiming to bring the needles back on the market by the end of 2026. This supply disruption could hinder the company's ability to meet demand for its breast biopsy guidance systems and related products, potentially leading to lost revenue and customer dissatisfaction.
The company's P/E ratio of 31.67 is relatively high compared to the broader healthcare sector, indicating that investors are paying a premium for Hologic's growth prospects. This valuation may leave little room for error if the company fails to meet future earnings expectations, increasing the risk of a significant stock price correction.
Hologic, Inc. has a beta of 0.70, which suggests that the stock is less volatile than the overall market. While this may be seen as a positive for risk-averse investors, it also means that the stock may underperform during periods of strong market rallies, limiting its potential for capital appreciation compared to higher-beta healthcare stocks.

HOLX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $79.13, with a high forecast of $90.00 and a low forecast of $76.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 12 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.

According to analysts, Hologic's stock has a predicted upside of 4.10% based on their 12-month stock forecasts.

Analysts like Hologic less than other "healthcare" companies. The consensus rating score for Hologic is 2.00 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how HOLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Hologic Recommendations

MarketBeat monitors more than a dozen sources for Hologic analyst ratings, with the most recent rating issued on 1/28/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.